MODERNA, MERCK UNVEIL MRNA-BASED CANCER VACCINE: HOW WELL DOES IT CUT SPREAD?
Fri 21 August 2026: Moderna and Merck announced that their personalized mRNA cancer vaccine Intismeran cut the risk of melanoma recurrence and metastasis in a late-stage trial. The breakthrough in this emerging area of cancer therapy drove Moderna’s shares up by as much as 160 percent. Interim results of the study released on Wednesday found […]
Continue Reading
